Seneschal Advisors’s Puma Biotechnology PBYI Stock Holding History

Seneschal Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$249	Buy	+25	New	+$220	﹤0.01%	545

Other funds holding PBYI

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

O'Shaughnessy Asset Management Stamford, Connecticut $23.6B AUM 34.05% 1-Year Est. Return

Seneschal Advisors's PBYI Position: Q3 2026 in Review

Seneschal Advisors opened a new position in Puma Biotechnology (PBYI) in Q3 2026: 25 shares worth $249. The stake represents ﹤0.01% of the portfolio and ranks #545 among its holdings.

123 funds tracked by Wall St. Rank hold PBYI as of Q3 2026.

Seneschal Advisors held 25 shares of Puma Biotechnology worth $249 as of Q3 2026.
Puma Biotechnology was a new Seneschal Advisors position in Q3 2026.
Puma Biotechnology made up ﹤0.01% of Seneschal Advisors's portfolio in Q3 2026, its #545 holding.
123 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2026.

Based on Seneschal Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.